Business
Valeo Pharma Announces $4.0 Million Non-Brokered Private Placement of Non-Convertible Debentures
Valeo Pharma Announces $4.0 Million Non-Brokered Private Placement of Non-Convertible Debentures.
About this update from Valeo Pharma Inc.
[{"type":"text","content":"\n\n\n\nValeo Pharma Announces $4.0 Million Non-Brokered Private Placement of Non-Convertible Debentures\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\nValeo Pharma Announces $4.0 Million Non-Brokered Private Placement of Non-Convertible Debentures\nCanada NewsWire\nMONTREAL, April 14, 2021\n\n\n\n/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES/\nValeo insiders participate for $2.6 million MONTREAL, April 14, 2021 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (\"Valeo\" or the \"Company\"), a Canadian pharmaceutical company, announced today a non-brokered private placement of up to 4,000 unsecured non-convertible debentures units (the \"Debenture Units\") at a price of $1,000 per Debenture Unit for maximum gross proceeds of $4,000,000 (the \"Offering\"). \n\n \n \n \n \n \n \n\n \nEach Debenture Unit will consist of one (1) unsecured non-convertible debenture of the Company in the principal amount of $1,000 (each, a \"Debenture\") and 200 Class \"A\" share purchase warrants (each, a \"Warrant\"). Each Warrant will entitle the holder thereof to purchase one Class \"A\" Share of the Company (each, a \"Share\") at an exercise price of $1.60 at any time up to 24 months following the closing date of the Offering (the \"Closing Date\"). The Debentures will mature at the latest 9 months after the closing and will bear interest at a rate of 8% per annum from the date of issue, payable in cash, semi-annually in arrears. \n\"We are appreciative of the continued support from insiders and investors close to the Company  in this placement\", said Steve Saviuk, Valeo's Chief Executive Officer. \"This financing will strengthen our balance sheet at a time of three important product launches for Valeo, Enerzair® Breezhaler®, Atectura® Breezhaler® and Redesca™. Commercialized through two distinct sales forces, these products are key drivers to our growth ...